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SUMMARY
The Polycomb group (PcG) protein EZH2 possesses oncogenic properties for which the underlying
mechanism is unclear. We integrated in vitro cell line, in vivo tumor profiling, and genome-wide loca-
tion data to nominate key targets of EZH2. One of the candidates identified was ADRB2 (Adrenergic
Receptor, Beta-2), a critical mediator of b-adrenergic signaling. EZH2 is recruited to the ADRB2
promoter and represses ADRB2 expression. ADRB2 inhibition confers cell invasion and transforms
benign prostate epithelial cells, whereas ADRB2 overexpression counteracts EZH2-mediated onco-
genesis. ADRB2 is underexpressed inmetastatic prostate cancer, and clinically localized tumors that
express lower levels of ADRB2 exhibit a poor prognosis. Taken together, we demonstrate the power
of integrating multiple diverse genomic data to decipher targets of disease-related genes.INTRODUCTION
The Polycomb group (PcG) proteins are transcriptional
repressors important for preserving cellular identity (Ring-
rose and Paro, 2004) and maintaining pluripotency and
plasticity of embryonic stem cells (Boyer et al., 2006;
Lee et al., 2006). They function in multiprotein Polycomb
Repressive Complexes (PRCs), one of which is PRC2
(Levine et al., 2002). PRC2 includes SUZ12 (Suppressor
of Zeste 12), EED (Embryonic Ectoderm Development),Canand EZH2 (Enhancer of Zeste 2) and is essential for the
initial binding to target gene promoters (Rastelli et al.,
1993). EZH2 is a histone methyltransferase (HMTase) that
specifically methylates lysine 27 of histone H3 (H3K27),
thus leading to target gene silencing (Cao et al., 2002;
Kirmizis et al., 2004; Kuzmichev et al., 2002).
Dysregulation of EZH2 has recently been associated
withanumber of cancers, includingmelanoma, lymphoma,
and breast and prostate cancers (Bracken et al., 2003;
Varambally et al., 2002; Visser et al., 2001). EZH2 is aSIGNIFICANCE
The transcriptional corepressor EZH2 possesses oncogenic properties, perhaps through repressing critical tumor
suppressor genes. Herewe integratedmultiple diverse genomic data to nominate direct targets of EZH2.We found
that the EZH2-containing Polycomb Repressive Complexes 2 (PRC2) bind to the ADRB2 promoter and repress
ADRB2 expression. Importantly, ADRB2 inhibition induces cell invasiveness and transforms benign prostate
epithelial cells. ADRB2 activation in xenograft mouse models inhibits prostate cancer tumor growth in vivo.
Remarkably, tissuemicroarray analysis suggests that ADRB2may serve as a biomarker of prostate cancer aggres-
siveness. Therefore, the identification of ADRB2 as a direct target of EZH2 may have implications in prostate
cancer prognosis and therapeutic intervention.cer Cell 12, 419–431, November 2007 ª2007 Elsevier Inc. 419
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Silencing of ADRB2 by Polycomb in Prostate CancerFigure 1. Overview of the Integrative
Genomics Analysis used to Nominate
Direct EZH2 Transcriptional Targets with
Pathological Relevance
Transcriptional targets of EZH2 repression
in vitro were identified by expression profiling
of immortalized RWPE benign prostate epithe-
lial cells and H16N2 normal breast epithelial
cells treated with either EZH2 adenovirus or
EZH2 siRNA as described in the Supplemental
Experimental Procedures. This in vitro EZH2
repression signature (ERS) was evaluated for
its inverse association with EZH2 in vivo by
Kolmogorov-Smirnov (KS) (Lamb et al., 2003)
scanning of multiple microarray data sets of
human tumors in the Oncomine database
(Rhodes et al., 2004) (see Figure S1 for signifi-
cance of association). In vivo ERS was created
by selecting genes that showed the most sig-
nificant repression by EZH2 in vivo. In parallel,
a cohort of gene promoters occupied by the
PRC2 complex was identified by genome-
wide location analysis (Figure S2). The in vivo
ERS genes that are also physically bound by
the PRC2 complex were nominated as direct
EZH2 targets in cancer.biomarker of aggressive epithelial tumors, and its upregu-
lation correlates with poor prognosis (Bachmann et al.,
2006; Collett et al., 2006; Matsukawa et al., 2006; Raa-
phorst et al., 2003). Functional studies have demonstrated
that EZH2 is a bona fide oncogene. For example, EZH2
RNA interference results in growth arrest in multiple mye-
loma cells (Croonquist and Van Ness, 2005) as well as in
the TIG3 diploid human fibroblasts (Bracken et al., 2003),
whereas ectopic overexpression of EZH2 promotes cell
proliferation and invasion in vitro (Bracken et al., 2003;
Kleer et al., 2003; Varambally et al., 2002) and induces
xenograft tumor growth in vivo (Croonquist and Van Ness,
2005). However, the underlying mechanism of EZH2-
mediated oncogenesis remains unclear. In this study we
hypothesized that EZH2 induces tumorigenesis via direct
transcriptional repression of key tumor suppressor genes.
We integrated genome-wide expression and location data
to identify direct EZH2 targets in cancer. One of the most
promising target genes we identified was ADRB2 (Adren-
ergic Receptor, Beta-2).
ADRB2 is a G protein-Coupled Receptor (GPCR) of the
b-adrenergic signaling pathway. Polymorphisms of the
ADRB2 gene have been associated with increased risk of
breast and colorectal cancer (Takezaki et al., 2001). Stim-
ulation of ADRB2 elevates the intracellular level of cyclic
AMP (cAMP), which in turn controls awide range of cellular
processes via multiple mechanisms. In particular, activa-
tion of cAMP-Rap1 by ADRB2 has been shown to regulate
cell adhesion and cellular transformation (Price et al.,
2004). However, the role of ADRB2 in prostate cancer pro-
gression, especially in the context of Polycomb regulation,
has not been investigated. In this study, we demonstrate
that ADRB2 is a direct target of EZH2 and establish a role
for b-adrenergic signaling in prostate cancer progression.420 Cancer Cell 12, 419–431, November 2007 ª2007 Elsevier IRESULTS
Identification of ADRB2 as a Direct Target
of EZH2 in Prostate Cancer
The purpose of this study is to characterize key direct
targets of EZH2 that may confer its oncogenic properties.
As EZH2may regulate a large number of downstreammol-
ecules, we integrated multiple diverse genomic data and
applied a number of inclusion criteria for target gene selec-
tion, thus minimizing the false-positive rates (Figure 1). To
investigate gene expression regulatedbyEZH2dysregula-
tion, we profiled benign immortalized RWPE prostate and
H16N2 breast cell lines using 20k-element cDNA microar-
rays. As described in the Supplemental Data available with
this article online, we identified 139 features (representing
126 unique genes), defined as an ‘‘in vitro EZH2 Repres-
sion Signature (ERS),’’ that are repressed by EZH2 adeno-
virus overexpression compared to control adenovirus-
treated cells, as well as upregulated (derepressed) by
EZH2 RNA interference relative to control siRNA-treated
cells (Table S1). As EZH2 plays a critical role in human can-
cer progression, we were most interested in EZH2-regu-
lated genes with clinical relevance. To look for a subset
of the in vitro ERS genes with coordinate repression by
EZH2 in vivo, we interrogated several public gene expres-
sion data sets of human tumors from Oncomine (Rhodes
et al., 2004), including two prostate (Glinsky et al., 2004;
Yu et al., 2004) and two breast cancer data sets (Huang
et al., 2003; van ’t Veer et al., 2002), and the Global Cancer
Map data set consisting of 190 primary human tumors
(Ramaswamy et al., 2001). We selected these cancer pro-
filing data sets, as EZH2 is best characterized in prostate
and breast cancer. The expression pattern of the in vitro
ERSgenes as a group showedmarked inverse associationnc.
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Silencing of ADRB2 by Polycomb in Prostate Cancerwith EZH2 transcript levels in all data sets (Figure S1). Out
of these, 23 individual genes were significantly downregu-
lated (p < 0.05 by Student’s t test) in tumors with higher
levels of EZH2 and thus selected as an ‘‘in vivo ERS’’ for
further investigation. Notably, a large number of these
genes have been previously implicated in cell proliferation
and cell adhesion.
EZH2 is a transcriptional repressor that may regulate
downstream gene expression either through direct tran-
scriptional regulation or by subsequent effects. To deter-
mine primary targets of EZH2, we mapped the genome-
wide location of the PRC2 complex using antibodies
against SUZ12, which has been successfully studied
for large-scale promoter occupancy (Boyer et al., 2006;
Bracken et al., 2006; Kirmizis et al., 2004; Lee et al., 2006).
We examined two prostate cancer cell lines, PC3 and
LNCaP, to increase the robustness of target genes. As
described in the Supplemental Data, we identified 85
PRC2-occupied genes in PC3 cells and 78 in LNCaP.
Out of these, we observed a remarkable overlap of 63
genes, suggesting the accuracy of this assay (Table S2).
In addition, we validated a randomly selected set of three
putative targets (NAT1, TUBB, and ZIC1) by conventional
chromatin immunoprecipitation (ChIP) followed by PCR
(ChIP-PCR) assay (Figure S2).
We compiled gene expression and promoter binding
data in order to identify direct EZH2 targets in prostate
cancer. Out of the 23 in vivo ERS genes identified from
our transcriptome analysis, two genes, namely ADRB2
and IGFBP2, are directly occupied by PRC2. In this study
we characterized the role of ADRB2 in the context of EZH2
oncogenic function in prostate cancer, as ADRB2 has
been previously implicated to have a role in cell growth,
adhesion, and transformation (Bos, 2005).
EZH2 Represses Transcript and Protein
Levels of ADRB2
To confirm that EZH2 represses ADRB2, we experimen-
tally overexpressed EZH2 by adenoviral infection of multi-
ple benign prostate and breast cell lines. Quantitative RT-
PCR demonstrated significantly reduced levels of ADRB2
transcript in response to EZH2 overexpression relative to
adenoviral vector control cells (Figure 2A and Figure S3).
This downregulation of ADRB2 was not observed with
the overexpression of an EZH2 mutant (EZH2DSET) lack-
ing the SET domain that is responsible for the HMTase
activity of EZH2. To determine whether ADRB2 protein is
coordinately regulated, we performed immunoblot analy-
sis of ADRB2 and observed a major band of predicted
size (47 kDa), supporting the specificity of the antibody
(Figure S3). Consistent with the changes at the transcript
level, EZH2 overexpressionmarkedly reduced the expres-
sion of ADRB2 protein when compared to the vector and
EZH2DSET controls (Figure 2B). Additionally, to localize
ADRB2 and EZH2proteins in cells, we performed confocal
immunofluorescent staining in the H16N2 primary breast
cell lines following vector or EZH2 adenoviral infection.
As expected, we found ADRB2 staining primarily in the
cell membrane/cytoplasm but EZH2 protein in the cellCannucleus (Figure 2C). Notably, in cells infected with EZH2
adenovirus, thus exhibiting strong EZH2 nuclear staining,
we observed a marked reduction in ADRB2 staining. By
contrast, the vector-infected cells demonstrated absent/
low EZH2 and high ADRB2 expression.
We have observed that ADRB2 is in general expressed
at lower levels in prostate cancer cells compared to benign
prostate epithelial cells, being opposite or inverse to EZH2
expression (data not shown). We hypothesized that this
low level of ADRB2 in prostate cancer cells may be due
to its repression by high EZH2. To test this hypothesis
we examined whether EZH RNA interference can dere-
press ADRB2 expression in cell line models. Immunoblot
analysis demonstrated upregulated ADRB2 protein levels
in response to transient EZH2 knockdown (Figure 2D).
This upregulation is more prominent in LNCaP and PC3
prostate cancer cells (over 2-fold) than in primary cell lines
(less than 2-fold). As transient RNA interference of EZH2
only moderately induces ADRB2, we attempted to estab-
lish DU145-shEZH2 cell lines with long-term inhibition of
EZH2 using short-hairpin RNAs (shRNAs) followed by
selection of stable colonies. Stable inhibition of EZH2 led
to a marked increase of ADRB2 protein level (Figure 2E).
Importantly, we observed a strong negative association
(r = 0.98, p = 0.004) between EZH2 and ADRB2 protein
levels in stable DU145-shEZH2 colonies with varying de-
grees of EZH2 inhibition, thus providing compelling evi-
dence for EZH2-mediated repression of ADRB2. To assure
that EZH2 regulationofADRB2occurs at the transcript level,
we examined ADRB2 and EZH2 transcripts by qRT-PCR.
We demonstrated that transient EZH2RNA interference up-
regulates ADRB2 mRNA in both the MDA-MB-231 breast
and the DU145 prostate cancer cell lines (Figure 2F).
We next examined whether this regulation has func-
tional relevance in vivo in human tumors.We hypothesized
that ADRB2 and EZH2 expression are negatively associ-
ated in human prostate tumors. To confirm this, we ana-
lyzed their expression in a set of three benign prostate
tissue samples, five clinically localized prostate cancers,
and seven metastatic prostate cancers by qRT-PCR. As
expected, our results demonstrated significant overex-
pression of EZH2 (p < 0.001 by Wilcoxon rank-sum test),
and yet marked downregulation of ADRB2 (p < 0.001 by
Wilcoxon rank-sum test) in metastatic prostate cancer
compared toorgan-confineddisease (Figure 2G).Remark-
ably, the expression levels of EZH2 and ADRB2 displayed
a strong negative association (r =0.67, p < 0.001) across
all samples, consistent with the repression of ADRB2 by
EZH2.
The EZH2-Containing PRC2 Complex Occupies
the ADRB2 Promoter
Expression regulation of target genes by a transcription
factor or cofactors may be mediated through direct inter-
action or secondary effects. Our genome-wide location
analysis suggested that the ADRB2 promoter may be
directly occupied by the PRC2 complex protein SUZ12 in
LNCaP and PC3 prostate cancer cells. We thus attempted
to recapitulate this protein-promoter binding in multiplecer Cell 12, 419–431, November 2007 ª2007 Elsevier Inc. 421
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Silencing of ADRB2 by Polycomb in Prostate CancerFigure 2. EZH2 Dysregulation Negatively Regulates ADRB2 Transcript and Protein
(A and B) Quantitative RT-PCR analysis for the expression ofADRB2 transcript (A) and immunoblot analysis of EZH2, ADRB2, and b-tubulin protein (B)
in immortalized primary human mammary epithelial cells (HME and H16N2) and prostate epithelial cells (RWPE and PrEC) following infection with
vector adenovirus (vector) or adenovirus encoding EZH2 or EZH2DSET mutant for 48 hr. See Figure S3 for an assessment of EZH2 transcript level,
a complete blot of ADRB2, and a higher exposure of EZH2 immunoblot. In immunoblots, the number underneath each band indicates the intensity of
corresponding band. Significant changes in EZH2 samples were evaluated relative to vector control.
(C) Immunofluorescence costaining of ADRB2 (red) and EZH2 (green) in H16N2 cells following adenoviral infection of control vector or EZH2 for 48 hr.
Scale bar, 10 mm.
(D) Immunoblot analysis of EZH2 and ADRB2 expression in multiple cell lines following RNA interference of EZH2 or a control. The protein levels of
b-tubulin are used as a loading control.
(E) Immunoblot analysis of EZH2 and ADRB2 in four stable DU145-shEZH2 colonies. DU145 cells were transfected with shRNA constructs targeting
EZH2 or a vector control, and selected for stable colonies. Individual DU145-shEZH2 colonies varied at the degree of EZH2 inhibition were selected
for assessment of the association between the expression levels of EZH2 and ADRB2.
(F) QRT-PCR analysis of EZH2 and ADRB2 transcripts in MDA-MB-231 and DU145 cancer cell lines following RNA interference of EZH2 or controls.
(G) QRT-PCR assessment of EZH2 and ADRB2 expression in prostate tumor specimens. Expression was determined in a cohort of three benign
prostate hyperplasia (benign), five localized prostate cancer (PCA), and seven metastatic prostate cancer (MET) tissues. For QRT-PCR experiments,
expression of target genes was normalized to the amount of the housekeeping gene GAPDH.
Error bars: n = 3, mean ± SEM, *p < 0.01 by Student’s t test.422 Cancer Cell 12, 419–431, November 2007 ª2007 Elsevier Inc.
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We first examined the LNCaP cells by ChIP using anti-
bodies against EZH2, SUZ12, the EZH2-mediated H3K27
trimethylation (3mH3K27), and an IgG antibody control. By
conventional ChIP-PCR assay using primers specific to
the ADRB2 promoter, we observed a strong enrichment
(over 30-fold, p < 0.001) by EZH2, SUZ12, and 3mH3K27
antibodies relative to the IgG control (Figure 3A).
It is important to investigate whether PRC2 binding on
the ADRB2 promoter is a robust phenomenon acrossmul-
tiple cell lines in vitro and prostate cancer tissues in vivo.
Thus, we performed ChIP analysis in a panel of additional
samples including the PC3 prostate cancer cell line and
293 human embryonic kidney cell line, as well as three
independent metastatic prostate cancer tissues. To pro-
vide controls for comparison we analyzed a previously
reported PRC2 target gene CNR1 (Kirmizis et al., 2004) as
a positive control and ACTIN as a negative control. Con-
sidering the limited amount of tissues available, ChIP-
enriched chromatin was amplified along with the whole-cell
extract (WCE) DNA to generate enoughmaterial for testing
multiple target genes. Using an equal amount of amplified
WCE and ChIP-enriched DNA, PCR analysis of target
geneswereevaluated forChIPenrichment relative toWCE.
Our results showed that the PRC2 complex and the
3mH3K27 mark co-occupy the promoters of ADRB2 and
CNR1, but not of ACTIN, in both PC3 (Figure 3B) and 293
cells (Figure 3C). The 3mH3K27markwas found to occupy
the ADRB2 promoter in all three metastatic prostate
cancer tissues, supporting repression of ADRB2 in vivo
(Figure 3D).
We next determinedwhether EZH2 expression is crucial
for PRC2 binding and H3K27 trimethylation of the ADRB2
promoter. By combining ChIP-PCR assay with RNA inter-
ference in the EZH2-high LNCaP prostate cancer cell, we
found that siRNA inhibition of EZH2 greatly decreased its
occupancy and, importantly, also reduced H3K27 trime-
thylation of the ADRB2 promoter and a positive control
(Figure 3E). Similarly, we examined the effect of EZH2
overexpression on PRC2 recruitment to the ADRB2 pro-
moter in the H16N2 primary breast cell line that expresses
low levels of endogenous EZH2. We used an antibody
against the Myc-tag of the EZH2 adenoviral constructs
for ChIP in order to precisely monitor the binding effects
of ectopic EZH2. Our results demonstrated the recruit-
ment of Myc-EZH2 to the ADRB2 promoter, but not of the
vector and the EZH2DSETmutant, this binding being sen-
sitive to SAHA, which inhibits HDAC activity and blocks
histone deacetylation (Figure 3F). Interestingly, ChIP show-
ed markedly increased occupancy of the PRC2 complex
proteins EED and SUZ12, as well as 3mH3K27 on the
ADRB2 promoter, upon EZH2 overexpression relative to
vector control, whereas the binding of acetylated H3
was strongly reduced, indicative of increased histone
deacetylation (Figure 3G). Further evaluation of SAHA
revealed a marked reduction of PRC2 binding and conse-
quent H3K27 trimethylation, and accumulation of acety-
lated H3 at the ADRB2 promoter (Figures 3H and 3I).
QRT-PCR analysis showed corresponding upregulationCanof ADRB2 transcripts following a time course of SAHA
treatment (Figure 3J).
Tan et al. have recently identified a small-molecule
compound, DZNep, which effectively inhibits the expres-
sion of PRC2 complex proteins (Tan et al., 2007). To fur-
ther confirm that ADRB2 is a transcriptional target of
PRC2 we examined the effect of DZNep across a batch
of breast and prostate cancer cell lines. Our results dem-
onstrated strong induction (derepression) of ADRB2 in all
cell lines tested (Figure 3K).
ADRB2 Inhibition Confers Cell Invasion and
Transforms Benign Prostate Epithelial Cells
We have shown above that ADRB2 is a direct target of
EZH2 transcriptional repression and is downregulated in
metastatic prostate cancer. Thus, we recapitulated this
event in benign prostatic epithelial cells to determine the
role of aberrant ADRB2 inhibition in prostate cancer. We
transfected the immortalized benign prostate epithelial
cell line RWPE with shRNA constructs targeting ADRB2
and selected for stable RWPE cells with ADRB2 knock-
down (RWPE-shADRB2) cells. The stableRWPE-shADRB2
cells showed a marked reduction in ADRB2 expression
relative to the vector-transfected control cells (Figure 4A).
We then investigated the effect of ADRB2 inhibition on
various oncogenic properties, such as cell proliferation,
invasion, and migration. Our results demonstrate that
inhibition of ADRB2 had no significant effect on cell prolif-
eration (Figure S4). However, we observed over 5-fold in-
crease of invasion in RWPE-shADRB2 cells compared to
the vector control (Figures 4A and 4B). Similarly, inactiva-
tion of ADRB2 by the ADRB2-specific antagonist ICI
118,551 significantly increased invasion in RWPE cells
(Figure 4C). Concordant with this, cell migration assay by
scratch wound healing showed that the RWPE-shADRB2
cells havemarkedly increasedmotility than the vector con-
trol cells (Figure S5). Taken together, these results suggest
that inhibition of ADRB2 in benign prostate cells confers
increased invasion, an important oncogenic phenotype.
To confirm the effect of ADRB2 on cell invasion in addi-
tional models, we activated ADRB2 using the agonist iso-
proterenol in DU145 prostate cancer cells and the invasive
RWPE-shADRB2 stable cells. The agonist-activated cells
showed significantly reduced invasion in both cell lines
(Figure S6). Concordantly, invasion assays revealed sig-
nificantly reduced invasion of the DU145-shEZH2 cells
with stable EZH2 knockdown and ADRB2 induction.
To directly link ADRB2 expression with oncogenic
EZH2 function, we investigated whether ADRB2 interferes
with EZH2-mediated cell invasion. We have previously
reported that overexpression of EZH2 increases invasion
in immortalized mammary epithelial cell line H16N2 (Kleer
et al., 2003). We investigated whether ADRB2 overexpres-
sion is able to rescue this effect by cotransfection of EZH2
and ADRB2. As expected, EZH2 overexpression dramat-
ically (12.9-fold, p < 0.001) increased invasion in H16N2
cells. By contrast, overexpression of ADRB2 led to a signif-
icant (3.6-fold, p < 0.001) reduction in EZH2-induced cell
invasion (Figure 4D).cer Cell 12, 419–431, November 2007 ª2007 Elsevier Inc. 423
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Silencing of ADRB2 by Polycomb in Prostate CancerFigure 3. The ADRB2 Promoter Is Occupied by PRC2 Complex Proteins and the H3K27 Trimethylation Mark
(A) Conventional ChIP-PCR analysis of EZH2 and SUZ12 occupancy and the level of H3K27 trimethylation (3mH3K27) of the ADRB2 promoter.
Chromatin immunoprecipitation (ChIP) were performed in LNCaP cells using antibodies against EZH2, SUZ12, 3mH3K27, and a control IgG.
ADRB2 promoter DNA was determined by PCR using primers specific to the ADRB2 promoter (Table S3), as percentage of whole-cell extract
(WCE) input DNA. Significance was calculated between antibody-enriched and IgG-enriched chromatin.
(B–D) EZH2, SUZ12, and 3mH3K27 occupancy on the ADRB2 promoter in PC3 metastatic prostate cancer cell line (B), in 293 embryonic kidney cell
line (C), and in three metastatic prostate cancer tissues (MET1-3) (D). ChIP-enriched chromatin was amplified by ligation-mediated PCR (LM-PCR)
along with the WCE DNA. An equal amount (100 ng) of ChIP-enriched and input amplicons was used to test target promoters by gene-specific
primers. The enrichment of a target promoter was assessed as the enrichment ratio of ChIP-enriched to WCE amplicons. CNR1 is a positive control
gene (Kirmizis et al., 2004), and ACTIN is a negative control. The dashed line indicates no enrichment. Significant enrichment of target genes was
assessed relative to ACTIN.
(E) EZH2 RNA interference blocks EZH2 and 3mH3K27 binding to the ADRB2 promoter.MYT1_distal is a positive control gene known to interact with
PRC2 complex (Kirmizis et al., 2004). ChIP experiments were performed using antibodies in LNCaP cells that were incubated with EZH2 siRNA or no
siRNA (mock) control. For the siRNA transfections, cells were treated with siRNA duplex for 72 hr, then replated and incubated with fresh siRNA
duplex for another 72 hr.
(F) Ectopically expressed EZH2 binds ADRB2 promoter in a histone deacetylation-dependent manner. ChIP was performed in H16N2 cells infected
with vector, EZH2DSET, or EZH2 adenovirus alone or in combination with SAHA treatment and analyzed by PCR using gene-specific primers. An
anti-Myc antibody was used for ChIP to specifically detect ectopically expressed EZH2 and its mutants.
(G) Ectopic overexpression of EZH2 increases PRC2 complex occupancy and H3K27 trimethylation and reduces H3 acetylation at the ADRB2
promoter. H16N2 cells infected by vector or EZH2 adenovirus were subjected to ChIP using the antibodies listed.424 Cancer Cell 12, 419–431, November 2007 ª2007 Elsevier Inc.
Cancer Cell
Silencing of ADRB2 by Polycomb in Prostate CancerFigure 4. ADRB2 Inhibition Confers Cell
Invasion and Transforms Benign Pros-
tate Epithelial Cells
(A and B) RWPE-shADRB2 cells were assayed
for invasion through a modified basement
membrane chamber assay. (Inset) Immunoblot
analysis of ADRB2 protein in stable vector and
RWPE-shADRB2 cell lines. The benign immor-
talized prostate cell line RWPEwas transfected
with shRNA constructs targeting ADRB2 or
control vector, and stable RWPE-shADRB2
or vector clones were generated. Scale bar,
100 mm.
(C) ADRB2 inactivation by antagonist in nonin-
vasive benign RWPE epithelial cells leads to in-
creased invasion. The noninvasive RWPE cells
were treated with 0, 1, or 10 mM of an ADRB2-
specific antagonist ICI 118,551 and assessed
by invasion assay.
(D) ADRB2 activation interferes with EZH2-me-
diated cell invasion. H16N2 cells were infected
with vector or EZH2 alone or in combination
with ADRB2. In this panel, the significance of
invasion in cells treated with EZH2 only was
evaluated relative to vector control, whereas
cells treated by EZH2 in combination with
ADRB2 were evaluated relative to the EZH2-
treated cells.
(E and F) ADRB2 inhibition in RWPE benign
prostate epithelial cells, either by shRNA
targeting ADRB2 (RWPE-shADRB2) (E) or by
an ADRB2 antagonist ICI 118,551 (F), regulates
the expression of EMT biomarkers and cell
adhesion molecules.
Error bars: n = 3, mean ± SEM, *p < 0.001.We examined the stable RWPE-shADRB2 cells for other
malignant phenotypes besides cell invasion and migra-
tion. Interestingly, we observed that the RWPE-shADRB2
cells display a mesenchymal phenotype with fibroblast-
like shape, whereas the vector control cells appear more
rounded (Figure S7). Importantly, this morphological con-
version highly resembles the converse of the mesenchy-
mal-to-epithelial transition by constitutively active Rap1A,
a primary downstream effector of b-adrenergic signaling
(Price et al., 2004). To confirm that ADRB2 inhibition in fact
transformed the RWPE benign prostate epithelial cells, we
examined the expression of typical mesenchymal bio-Cancmarkers and adhesion molecules. Immunoblot analysis
demonstrated markedly increased expression of the mes-
enchymal cell biomarkers vimentin andN-cadherin, andyet
a significant decrease of the expression of adhesion mole-
cules b-catenin and integrin b 4 (ITGB4) (Figure 4E). No sig-
nificant changes in E-cadherin expression were observed.
Interestingly, antagonist (ICI 118,551)-mediated inactiva-
tion of ADRB2 recaptured the expressional changes in
RWPE-shADRB2 cells (Figure 4F). Furthermore, to investi-
gate whether this property of ADRB2 has a link to EZH2
function, we overexpressed EZH2 in native RWPE cells.
Interestingly, EZH2 overexpression evoked expressional(H) Endogenous PRC2 complex occupies the ADRB2 promoter and is sensitive to the HDAC inhibitor SAHA. ChIP experiments were performed in
DU145 cells following control or SAHA treatment using the antibodies listed.
For (E)–(H), PCR was performed using antibody-enriched chromatin without LM-PCR amplification. Enrichment of target gene by a ChIP antibody is
assessed relative to the IgG control.
(I) PRC2 recruitment to the ADRB2 promoter after a time course of SAHA treatment. DU145 prostate cancer cells were treated with 1 mM SAHA and
harvested at 0, 0.5, 2, 6, 8, 12, 24, and 48 hr after treatment. ChIP was performed using antibodies against AceH3 and 3mH3K27. Standard qPCRwas
done using primers for ADRB2 promoter, and ChIP enrichment was evaluated as a percentage of input DNA.
(J) ADRB2 transcript was upregulated following SAHA treatment. QRT-PCR analysis of ADRB2 transcripts was done following a time course of SAHA
treatment. RPL13A was used for normalization as it was reported to be insensitive to HDAC inhibitors (Mogal and Abdulkadir, 2006).
(K) Marked upregulation of ADRB2 transcript by the PRC2-inhibiting compound DZNep. Cells were treated with 5 mM DZNep for 48 hr and were
harvested for RNA isolation and QRT-PCR analysis.
Error bars: n = 3, mean ± SEM, *p < 0.01 by Student’s t test.er Cell 12, 419–431, November 2007 ª2007 Elsevier Inc. 425
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ably, reactivation of ADRB2 in the EZH2-overexpressing
RWPE cells is able to reverse the effect induced by EZH2
overexpression (data not shown).
ADRB2 Inhibits Prostate Tumor Growth In Vivo
We have thus far established a role for b-adrenergic sig-
naling in cell migration, invasion, and transformation by
using in vitro cell line models. It is appealing to extend
this study to in vivo mouse models. We first tested the
effect of stable EZH2 knockdown, leading to consequent
ADRB2 induction (Figure 2E), on prostate tumor formation
by inoculating the EZH2/ADRB2+ DU145-shEZH2 cells
into nude mice. Intriguingly, tumors developed in all con-
trol EZH2+/ADRB2 mice at 3 weeks after injection,
whereas the EZH2/ADRB2+ mice did not grow tumors
by 7 weeks after injection (Figure 5A).
To directly examine the effect of ADRB2 in in vivo pros-
tate tumor growth, we subcutaneously injected native
DU145 prostate cancer cells into nude mice. These mice
were then randomly separated into three groups (fivemice
per group) and treated, through intraperitoneal injections,
with either PBS or the ADRB2 agonist isoproterenol at 400
mg/day or 800 mg/day. Xenograft tumors started to grow
at 2 weeks after implantation. When compared with the
PBS-treated control group, isoproterenol-treated mice
developed significantly (two-sample Student’s t test,
p = 0.006) smaller tumors (Figure 5B).
ADRB2 Protein Level Predicts Prostate
Cancer Clinical Outcome
The repression of ADRB2 by oncogenic EZH2 and its
implication in cell invasion and tumorigenesis in both
in vitro and in vivo models suggest that reduced expres-
sion of ADRB2 may be associated with human prostate
cancer progression. To assess ADRB2 expression during
human prostate cancer progression, we examined a pros-
tate cancer microarray study (Varambally et al., 2005) that
profiled six benign prostate tissue samples, seven clini-
cally localized prostate cancers, and six metastatic pros-
tate cancers. We found that ADRB2 transcript is strongly
repressed (p = 0.003 by Student’s t test) in the meta-
static samples, being inversely associated (r = 0.85,
p < 0.0001) with EZH2 expression (Figure 5C). It is possi-
ble that ADRB2 may present in the stromal cells and
its downregulation in metastatic prostate cancer merely
reflects the decrease in the percentage of stroma. To ex-
clude this possibility, we examined ADRB2 expression in
a prostate cancer microarray profiling data set using laser
capture microdissected (LCM) epithelial cells (Tomlins
et al., 2007). Importantly, cDNA microarray analysis of
30 LCM PCA and 16 MET samples confirmed downregu-
lation (p < 0.001 by Student’s t test) of ADRB2 in meta-
static prostate cancer (Figure 5D).
To evaluate ADRB2 protein expression in prostate
tumors, ADRB2 immunohistochemistry was performed in
36 benign, 6 prostatic intraepithelial neoplasia (PIN), 82
clinically localized PCA, and 16MET tissues. As expected,
we observed ADRB2 staining primarily in epithelial cells426 Cancer Cell 12, 419–431, November 2007 ª2007 Elsevier In(Figure 5E). Overall, there was a significant difference in
the distribution ofmedian ADRB2 staining intensity among
the four groups (p < 0.0001 by Kruskal-Wallis test). Nota-
bly, the metastatic tumors had the weakest expression of
ADRB2.Most cases of low or absent ADRB2 stainingwere
observed in METs (Figures 5E and F). This led us to the
hypothesis that low ADRB2 protein levels may portend
the aggressiveness of clinically localized prostate cancer.
This would be in contrast to high EZH2 levels being indic-
ative of poor clinical outcome in patients with clinically
localized disease (Varambally et al., 2002).
We therefore examined the clinical outcome of the 82
patients with organ-confined prostate cancer, taking into
account clinical and pathological parameters. By Kaplan-
Meier analysis, a low product score (<240) indicative of
low ADRB2 staining was significantly (p = 0.002) associ-
ated with clinical failure, in comparison with high product
score (R240) indicative of strong ADRB2 staining (Fig-
ure 5G). Multivariate Cox proportional-hazards regression
analysis revealed that ADRB2 could predict clinical failure
independently of Gleason score, maximum tumor dimen-
sion, surgical margin status, and preoperative PSA (Table
1). With an overall recurrence ratio of 3.4 (95%CI: 1.5–7.8,
p = 0.004), it was by far the strongest predictor of clinical
failure in this model. In order to compare the ability of
ADRB2 status to predict outcomes beyond that given
with standard clinical parameters, we compared ADRB2
with a preoperative nomogram for predicting treatment
failure at 5 years (Kattan et al., 1998). As shown in Table
2, ADRB2 provides significant predictive power for patient
prognosis (p = 0.015, recurrence ratio = 2.7, 95% CI: 1.2–
6.0) that is both independent of the preoperative nomo-
gram and of greater significance. Taken together, ADRB2
is downregulated in metastatic prostate cancer, low
ADRB2 expression is associated with poor prognosis of
clinically localized prostate cancer, and ADRB2 expres-
sion provides additional prognostic information beyond a
typical clinical nomogram.
DISCUSSION
EZH2 is a transcriptional repressor that has been found
upregulated in a number of cancer types (Bachmann et al.,
2006;Collett et al., 2006; Varambally et al., 2002).Dysregu-
lation of EZH2 controls cell proliferation, cell invasion, and
transformation (Bracken et al., 2003; Croonquist and
Van Ness, 2005). However, it remains unknown how EZH2
overexpression leads to cancer initiation and progression.
Onemechanism is that the transcriptional repressor EZH2
may promote tumorigenesis by the repression of tumor
suppressor genes (Beke et al., 2007). Identifying direct
EZH2 target genes with potential tumor suppressor func-
tion may reveal novel prognostic/diagnostic biomarkers
and therapeutic targets. Thus, in this study we nominate
and evaluate potential targets of EZH2 and characterize
one of these target genes, ADRB2, in prostate cancer pro-
gression. In order to increaseour chanceof identifying truly
positive target genes, we have integrated multiple diverse
genomic data, as each of these data sets may have falsec.
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(A) The stable DU145-shEZH2 (EZH2/ADRB2+) cells have inhibited tumor growth in a xenograft mouse model. Mice were divided into two groups
(n = 5) and inoculated with control or EZH2/ADRB2+ DU145 cells (Figure 2E). Tumor sizes were evaluated once per week. All control mice formed
tumors by 2 weeks postinoculation, where as no tumors formed by the EZH2/ADRB2+ cells at 7 weeks postinoculation. Error bars: n = 5, mean ±
SEM.
(B) ADRB2 activation inhibits tumor growth in a xenograft mouse model. Mice were injected with DU145 cells, were randomly divided into three
groups (n = 5 per group), and received intraperitoneal injection of either PBS or the ADRB2 agonist Isoproterenol (at 400 mg/day or 800 mg/day)
once per day. Tumor sizes were evaluated once per week. Isoproterenol treatment significantly (two-sample Student’s t test, p = 0.006) inhibited
xenograft tumor growth. Error bars: n = 5, mean ± SEM.
(C) Affymetrix microarray analysis of grossly dissected tissues including six benign, seven clinically localized (PCA), and six metastatic prostate
cancer (METs) tissues. Box plot of ADRB2 (red) and EZH2 (blue) expression in each category is shown.
(D) cDNA microarray analysis of laser capture microdissected (LCM) prostate cancer epithelial cells for ADRB2 expression. Box plot of ADRB2
expression in a cohort of 30 LCM localized prostate cancer (PCA, in blue) and 16 metastatic prostate cancer (MET, in red) tissues is shown.
(E) Representative immunostaining of ADRB2 in benign prostate and localized (PCA) and metastatic (MET) prostate cancer. Scale bar, 100 mm.
(F) Histogram of ADRB2 immunostaining as assessed using prostate cancer tissue microarray analysis (TMA). Samples were scored (range: 1, 2, 3,
and 4) based on median staining intensity. A score of 4 and higher is considered as strong staining, while scores of 3 and less are considered weak
staining. PIN stands for prostate intraepithelial neoplasia.
(G) Kaplan-Meier analysis shows that individuals with clinically localized PCA that have lower expression of ADRB2 (low intensity and low percentage
of staining) have a greater risk for disease recurrence after prostatectomy (p = 0.002).Cancer Cell 12, 419–431, November 2007 ª2007 Elsevier Inc. 427
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Silencing of ADRB2 by Polycomb in Prostate CancerTable 1. Multivariate Cox Regression Analysis of Association of ADRB2 and Clinical Parameters with Cancer
Recurrence
Recurrence Ratio 95% CI p
ADRB2 (product scoreR 240 versus < 240) 3.423 1.500 7.808 0.004
Gleason (R7 versus%6) 1.604 0.607 4.241 0.341
Tumor size (R2 cm versus <2 cm) 1.306 0.526 3.239 0.565
Surgical margin (positive versus negative) 1.737 0.807 3.740 0.158
Preoperative PSA (>7, 4–7,%4) 1.519 0.852 2.707 0.156
Note: Sample size is 82 with 29 recurrences. Product score indicates the product of ADRB2 intensity measure (range: 1, 2, 3, and 4)
and percentage of staining measure (range: 0–100).positives. In addition, as noted by Squazzo et al. (2006)
with regards to thecell type specificity ofPcG target genes,
the targets identified in this study, which is oriented specif-
ically toward prostate and breast cancer cells, may not be
universal to other cell types. As EZH2 functions as a tran-
scriptional repressor, it may have profound effects on tar-
get gene regulation; it is possible thatmultiple downstream
effectors of EZH2 exist and may likewise mediate EZH2
function as redundant pathways. However, our study sug-
gests that ADRB2 is one of these targets with clinical
relevance.
We providemultiple lines of evidence to supportADRB2
as a target of EZH2-mediated transcriptional repression.
First, our analysis revealed an inverse association between
EZH2 and ADRB2 expression across multiple microarray
tumor profiling data sets. By qPCR we confirmed this
across a cohort of benign and prostate cancer samples.
To exclude the possibility that ADRB2 downregulation in
metastatic prostate cancer couldbe abias of stromal cells,
we examined microarray data using LCM tumor samples.
Second, we have experimentally altered EZH2 expres-
sion in vitro across multiple prostate and breast cell lines
and investigated the corresponding changes in ADRB2
expression. Multiple techniques, including adenovirus
overexpression, siRNA-mediated transient inhibition, and
shRNA-mediated stable inhibition, were used. Addition-
ally, we have examined expression changes at both the
transcript and protein levels. We have also performed
immunofluorescent costaining of ADRB2 andEZH2 in vitro
and tissue microarray staining of ADRB2 to examine
expression changes at the cellular level. Taken together,
our results provide compelling evidence that ADRB2 is
a target for repression by EZH2 and that it is upregulated
in metastatic prostate cancer.428 Cancer Cell 12, 419–431, November 2007 ª2007 ElsevierBy ChIP assay, we showed that the ADRB2 promoter is
occupied by the EZH2-containing PRC2 complex proteins
and trimethylated at H3K27 across multiple cell lines as
well as metastatic prostate cancer specimens. These
results support the interaction between the EZH2 protein
and the ADRB2 promoter, thus providing a mechanism
for the repression of ADRB2 by EZH2. Furthermore, we
demonstrated that ectopically expressed EZH2 recruits
other PRC2 complex proteins to the ADRB2 promoter
and the occupancy of the ADRB2 promoter by the PRC2
complex can be removed by RNA interference of EZH2.
Importantly, we observed that ADRB2 expression can be
derepressed by PRC2-inhibiting compounds. These are
consistent with the observed changes in ADRB2 expres-
sion following EZH2 overexpression or inhibition.
The EZH2-mediated repression of ADRB2 and its down-
regulation in metastatic prostate cancer suggest a role of
ADRB2 in tumor suppression. ADRB2 is a member of the
seven-transmembrane receptors, which are often referred
to asGPCRs. Ligandbinding onADRB2 strongly increases
its affinity with G protein and elevates the level of intra-
cellular cAMP,which regulates awide rangeof cellular pro-
cesses by multiple mechanisms (Daaka, 2004; de Rooij
et al., 1998). Stimulation of ADRB2 hasbeen previously im-
plicated in cell proliferation (Stork and Schmitt, 2002) and
cell adhesion (Bos, 2005; Price et al., 2004). A hallmark of
cAMP/b-adrenergic signaling is its ability to inhibit cell pro-
liferation in some cell types while stimulating cell growth in
others (Stork and Schmitt, 2002). In this study, however,
we did not observe an effect of ADRB2 on cell proliferation
in prostate cells.We observed, instead, that ADRB2 inhibi-
tion markedly increased invasiveness of benign prostate
epithelial cells and immortalized normal breast epithelial
cells, partially counteracting EZH2-mediated cell invasion.Table 2. Multivariate Cox Regression Analysis of Association of ADRB2 and Preoperative Nomogram with Cancer
Recurrence
Recurrence Ratio 95% CI p
ADRB2 (product scoreR 240 versus < 240) 2.694 1.212 5.989 0.015
Preoperative nomogram for 5 year recurrence-free prediction 1.019 1.003 1.036 0.020
Tumor size (R2 cm versus <2 cm) 1.146 0.470 2.791 0.764
Surgical margin (positive versus negative) 1.612 0.736 3.531 0.233
Age 1.009 0.960 1.061 0.716Inc.
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benign prostate epithelial cells, leading to changes in cell
morphology and gene expression that are typical for epi-
thelial-to-mesenchymal transition (EMT). Although ADRB2
has long been implicated in cell adhesion, our report dem-
onstrates its additional roles in cell invasion and EMT.
These results are consistent with the repression of ADRB2
by oncogenic EZH2 and the downregulation of ADRB2 in
aggressive prostate tumors. Our xenograft mouse models
suggest that ADRB2-activating compounds may have
potential utility in treating prostate cancer in patients.
Importantly, by immunohistochemistry we found much
lower or absent ADRB2 staining in metastatic prostate
cancer relative to clinically localized tumors and benign
prostate specimens. Significantly, analysis of ADRB2
staining in 82 localized prostate cancers with 29 cancer
recurrence correlates ADRB2 expression with prostate
cancer prognosis. The ADRB2 status provides additional
predictive power beyond that achieved with standard pre-
operative nomograms. Low ADRB2 expression is signifi-
cantly associated with PSA recurrence, thus indicating
ADRB2 as a potential prognostic biomarker of aggressive
prostate cancer. Therefore, we show that characterization
of EZH2 direct target genes may be useful for the identifi-
cation of novel cancer biomarkers and potential therapeu-
tic targets.
In summary, we integrated multiple genomics data to
identify ADRB2 as a direct target of EZH2-mediated tran-
scriptional repression. We determined a role of ADRB2 in
regulating cell invasion and tumorigenesis, thus providing
a PcG target relevant to EZH2’s oncogenic function and
suggesting a functional link between PcG silencing and
b-adrenergic signaling. In human prostate cancer, ADRB2
levels can be used as a prognostic biomarker and possibly
to identify patients with aggressive disease (i.e., those
with low levels of ADRB2). Further studies in the context
of larger prospectively gathered cohorts will allow investi-
gators to evaluate ADRB2 as a prognostic biomarker in
different populations. Taken together, we demonstrate
the power of integrating multiple diverse genomics data
to decipher critical targets of disease-related genes.
EXPERIMENTAL PROCEDURES
Cell Culture
LNCaP and DU145 prostate cancer cells were cultured in RPMI sup-
plemented with 10% fetal bovine serum (Invitrogen, Carlsband, CA).
RWPE cells were grown in keratinocyte serum-free medium (Invitro-
gen) supplemented with 5 ng/ml human recombinant EGF and 0.05
mg/ml bovine pituitary extract. H16N2 immortalized human mammary
epithelial cells were grown in Ham’s F12 with supplements. Detailed
information aswell as treatment to cells is described in the Supplemental
Experimental Procedures.
Human Tissue Specimens
Prostate cancer tissues were collected from the Rapid Autopsy
Program, which is part of the University of Michigan Prostate Cancer
Specialized Program of Research Excellence (S.P.O.R.E.) Tissue
Core. Tissue samples were collected with informed consent of the
patients and prior Institutional Review Board approval.CanTissue Microarray Analysis
The clinically stratified prostate cancer tissue microarrays used in this
study have been described previously (Varambally et al., 2002). TMA of
ADRB2 expression in prostate cancer was performed according to
established protocols (Varambally et al., 2005). For Kaplan-Meier anal-
ysis, clinical failure was defined as either an increase of 0.2 ng ml1
PSA or recurrence of disease after prostatectomy, such as develop-
ment of metastatic cancer. ADRB2 protein level in each sample was
measured based on its product score, which is a product of ADRB2
staining intensity measure at the levels of 1, 2, 3, and 4, and the per-
centage of positive staining measure ranged from 0% to 100%.
Gene Expression Analysis
Total RNA was isolated at various times after EZH2 infection (RWPE 3,
6, 12, 24, 48, 72 hr; H16N2 6, 12, 24, 48, 72 hr), or at 48 hr after EZH2
RNA interference in both cell lines. Gene expression analysis was done
as described using 20k-element cDNA microarrays covering 15,495
UniGene clusters (Dhanasekaran et al., 2005). The hybridized slides
were scanned by Axon scanner (Axon Instruments Inc., Union City,
CA), the images were analyzed usingGenepix, and data were analyzed
as described in detail in the Supplemental Experimental Procedures.
Gene expression microarray data discussed in this study have been
deposited in the NCBI’s Gene Expression Omnibus (GEO) with acces-
sion number GSE8144 and GSE8145.
ChIP and Genome-wide Location Analysis
ChIP was performed according to published protocols (Boyd et al.,
1998). Genome-wide location analysis was performed per manufac-
turer’s instruction (Aviva Systems Biology, San Diego, CA). Modifica-
tions and experimental details are indicated in the Supplemental
Experimental Procedures. Primer sequences used for ChIP are listed
in Table S3. Genome-wide location data discussed in this study have
been deposited in the NCBI’s Gene Expression Omnibus (GEO) with
accession number GSE5596.
Murine Prostate Tumor Xenograft Model
All procedures involving mice were approved by the University Com-
mittee on Use and Care of Animals (UCUCA) at the University of Mich-
igan and conform to their relevant regulatory standards. Five-week-old
male nude athymic BALB/c nu/nu mice (Charles River Laboratory,
Wilmington, MA) were used for examining the tumorigenicity. To eval-
uate the role of EZH2 downregulation in tumor formation, the EZH2/
ADRB2+ DU145 cells or the vector control cells were propagated and
inoculated by subcutaneous injection into the dorsal flank of ten mice
(n = 5 per group). To evaluate the role of b-adrenergic signaling in
tumor formation, DU145 cell was propagated and treated with PBS or
10 mM Isoproterenol at 24 hr prior to harvest. Cells were then harvested
and suspended in a 0.1 ml PBS with or without treatment of 10 mM Iso-
proterenol. A total of 15 mice (n = 5 per group) were each implanted
with 5 3 106 DU145 cells into the dorsal flank subcutaneously. Treat-
ment started 24 hr after implantation. Each group was administered
daily by intraperitoneal injection with either PBS or Isoproterenol (at
400 mg/day or 800 mg/day). Tumor size was measured every week,
and tumor volumes were estimated using the formula (p/6) (L 3 W2),
where L = length of tumor and W = width.
Supplemental Data
The Supplemental Data include supplemental text, seven supplemen-
tal figures, and three supplemental tables and can be found with this
article online at http://www.cancercell.org/cgi/content/full/12/5/419/
DC1/.
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